Tissue healing accelerant - Carmell Corporation
Latest Information Update: 28 May 2024
At a glance
- Originator Carnegie Mellon University
- Developer Carmell Corporation
- Class Blood proteins; Skin disorder therapies
- Mechanism of Action Fibroblast growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Alopecia; Tendon injuries; Wounds
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Alopecia in USA
- 28 May 2024 No recent reports of development identified for preclinical development in Tendon injuries in USA
- 28 May 2024 No recent reports of development identified for preclinical development in Wounds in USA